Recommendation history:the last 12 months
Every investment recommendation disseminated in the last 12 months, including the ones that expired, were superseded or ended in a loss.
The 12-month record
279entries
on 144 stocks
- in force
- 144
- superseded
- 135
- expired
- 0
Direction of the rating
- Positive69
- Neutral91
- Negative119
Producer and distributor: Ploutos AI
Responsible for producing the research: Nikolaos Drongitis, Founder & Head of Investment Research
Updated November 16, 2026, 18:16 UTC
Past performance does not guarantee future results. Realized returns can differ materially from the tracked numbers shown.
Every entry
Newest first, with every field the disclosure names.
- GOOGLAlphabet Inc.RatingMarket Performneutral
- IBMINTERNATIONAL BUSINESS MACHINES CORPRatingMarket Performneutral
- MRVLMarvell Technology, Inc.RatingUnderperformnegative
- BLBDBlue Bird CorpRatingMarket Performneutral
- BLBDBlue Bird CorpRatingMonitorneutral
- IESCIES Holdings, Inc.RatingMonitorneutral
- IRENIREN LtdRatingUnderperformnegative
- IRENIREN LtdRatingUnderperformnegative
- ETONEton Pharmaceuticals, Inc.RatingUnderperformnegative
- METAMeta Platforms, Inc.RatingOutperformpositive
| Security | Dissemination | Type and ISIN | Rating | Price and fair value | Horizon and status | Responsible and MAR | Changes |
|---|---|---|---|---|---|---|---|
| GOOGLAlphabet Inc. | 2026-06-0917:24 UTC | US02079K3059Common Stock | Market Performneutral | $362.39Fair value$123.65 to $254.79 | SupersededLong-term (365 days)valid until 2027-06-09 UTCStatusOpen position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | 2026-08-21 UTCCorrectionNone |
| IBMINTERNATIONAL BUSINESS MACHINES CORP | 2026-06-0910:44 UTC | — | Market Performneutral | $280.82Fair value$161.07 to $290.52 | SupersededLong-term (365 days)valid until 2027-06-09 UTCStatusOpen position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | 2026-07-10 UTCCorrectionNone |
| MRVLMarvell Technology, Inc. | 2026-06-0910:40 UTC | — | Underperformnegative | $288.85Fair value$58.02 to $85.73 | SupersededLong-term (365 days)valid until 2027-06-09 UTCStatusNegative rating tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | 2026-06-15 UTCCorrectionNone |
| BLBDBlue Bird Corp | 2026-06-0613:42 UTC | US0953061068Common Stock | Market Performneutral | $69.68Fair value$44.88 to $111.85 | SupersededMedium-term (180 days)valid until 2026-12-03 UTCStatusNo position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | 2026-06-26 UTCCorrectionNone |
| BLBDBlue Bird Corp | 2026-06-0611:29 UTC | US0953061068Common Stock | Monitorneutral | $69.68Fair value$44.88 to $111.85 | SupersededMedium-term (180 days)valid until 2026-12-03 UTCStatusClosed (reached the target) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | 2026-06-06 UTCCorrectionNone |
| IESCIES Holdings, Inc. | 2026-06-0520:40 UTC | — | Monitorneutral | $743.76Fair value$184.78 to $446.84 | ActiveMedium-term (180 days)valid until 2026-12-02 UTCStatusClosed (safety stop) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | NoneCorrectionNone |
| IRENIREN Ltd | 2026-06-0520:31 UTC | USQ4982L1090Common Stock | Underperformnegative | $53.13Fair value$9.43 to $12.60 | SupersededLong-term (365 days)valid until 2027-06-05 UTCStatusNegative rating tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | 2026-06-14 UTCCorrectionNone |
| IRENIREN Ltd | 2026-06-0519:49 UTC | USQ4982L1090Common Stock | Underperformnegative | $53.13Fair value$9.43 to $12.60 | SupersededLong-term (365 days)valid until 2027-06-05 UTCStatusNegative rating tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | 2026-06-05 UTCCorrectionNone |
| ETONEton Pharmaceuticals, Inc. | 2026-06-0519:44 UTC | — | Underperformnegative | —Fair value$14.78 to $20.97 | ActiveMedium-term (180 days)valid until 2026-12-02 UTCStatusNo position tracked | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeNot determined | NoneCorrectionNone |
| METAMeta Platforms, Inc. | 2026-06-0505:59 UTC | US30303M1027Common Stock | Outperformpositive | $627.57Fair value$537.36 to $918.87 | SupersededLong-term (365 days)valid until 2027-06-05 UTCStatusClosed (reached the target) | Nikolaos DrongitisFounder & Head of Investment ResearchMAR scopeIn scope | 2026-06-14 UTCCorrectionNone |
The full analysis
What do a company's filings show?
Every rating in the table came out of an analysis of the company's SEC filings. The full Ploutos AI analysis reads everything a company has filed and shows what stands behind its figures, with a source for each one.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which recommendations does the table include?
The table contains every investment recommendation disseminated during the previous 12 months that falls within the scope of this record, without selection by outcome. For additional transparency, Ploutos AI may also display recommendations for instruments to which it voluntarily applies the same standards. These are separately identified.
What is shown for each recommendation?
Each entry shows: dissemination date and time with timezone, issuer and instrument, ticker and ISIN where available, the name and job title of the person responsible for production, rating and direction, market price at dissemination with its own timestamp, fair value or price target where published, time horizon and validity period, current status, any superseding recommendation and any visible correction.
What happens when a recommendation is superseded or corrected?
When a recommendation is superseded or corrected, the original entry stays as published: it is not deleted or silently altered, and the correction is shown separately.
Do I need to sign up to see the full record?
The list is available free of charge and without registration. Filters or pagination do not restrict access to the complete record.
Why are some analyses not in the table?
Outside the table: 29 analyses that left no entry on the list, either because they rated no stock or because the published output cannot be read, and 0 ratings with no recognised tier. The counts are published so that nothing is removed in silence.
Why are the Market Radar picks not here?
The weekly Market Radar lists are not included here. Radar selections carry no individual rating tier and are recorded separately.
The public record
The pages where the method shows in practice, in full and unselected.